Organon Secures FDA Approval Extending NEXPLANON Use to Five YearsZacks Investment Research • 01/20/26
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: ReportBenzinga • 01/20/26
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg RadiopaqueBusiness Wire • 01/17/26
Organon (OGN) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 01/15/26
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and NorwayBusiness Wire • 01/08/26
Organon (OGN) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 12/22/25
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the USBusiness Wire • 11/17/25
Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/10/25
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to LaborieBusiness Wire • 11/07/25
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025Business Wire • 11/06/25
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens BermanGlobeNewsWire • 10/27/25
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee InvestigationBusiness Wire • 10/27/25